Nerviano Medical Sciences (NMS) is focused on discovery and clinical development of small molecule NCEs for oncology. The Company takes innovative approaches on novel mechanisms of action and drug targets to bring first- and best-in-class personalized medicines to cancer patients. Nerviano's current pipeline consists of NCEs, which originate from it's industrially renowned kinase inhibitor drug discovery platform which comprises an ever-evolving chemical collection with broad intellectual property coverage, discovery know-how and technologies. Nerviano's kinase platform has enabled the company to out-license IP rights on approved innovative medicines such as encorafenib and entrectinib and currently includes preclinical to clinical stage products, which are being developed both in house and with partners, including four proprietary clinical assets in Phase I/II studies. Moreover, the development of the company's payload linker platform allows an extension of our pipeline with innovative payload linkers for next generation ADC production. NMS combines the flexibility of a biotech with the quality of a big pharma.